RA Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

RA Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-590,218	Closed	-$4.27M	–	59
2023 Q1	$4.27M	Hold	590,218	–	–	0.1%	55
2022 Q4	$7.57M	Hold	590,218	–	–	0.15%	54
2022 Q3	$8.34M	Buy	590,218 +207,190	+54%	+$2.72M	0.18%	62
2022 Q2	$4.72M	Buy	+383,028	New	+$5.69M	0.13%	73
2021 Q4	–	Sell	-347,668	Closed	-$10.2M	–	104
2021 Q3	$10.2M	Buy	347,668 +168,114	+94%	+$5.12M	0.14%	75
2021 Q2	$4.55M	Buy	+179,554	New	+$4.1M	0.07%	87

Other funds holding WHWK

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

RA Capital Management's WHWK Position: Q2 2023 in Review

RA Capital Management sold out of Whitehawk Therapeutics (WHWK) in Q2 2023, closing a stake of 590,218 shares — an estimated $4.27M sold.

RA Capital Management first reported a position in WHWK in Q2 2021 and held it in 6 quarters. The position peaked at $10.2M in Q3 2021. 67 funds tracked by Wall St. Rank hold WHWK as of Q2 2023.

RA Capital Management reported no remaining Whitehawk Therapeutics position as of Q2 2023 after selling out during the quarter.
RA Capital Management sold 590,218 Whitehawk Therapeutics shares in Q2 2023, an estimated $4.27M.
RA Capital Management first reported a position in Whitehawk Therapeutics in Q2 2021 and held it in 6 quarters.
RA Capital Management's Whitehawk Therapeutics position peaked at $10.2M in Q3 2021.
67 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2023.

Based on RA Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.